John Reynders, Alexion Pharmaceuticals, Inc.

John Reynders John Reynders, Ph.D. MBA, is Vice President, Data Sciences, Genomics, and Bioinformatics at Alexion. In his role, Dr. Reynders leads Alexion’s Data Sciences, Genomics, and Bioinformatics (DGB) organization in the design, building, and deployment of DGB solutions spanning R&D, Commercial, Strategy, and Business Development. These solutions include a graph-database of the entire rare-disease landscape annotated with prevalence, severity, competitive intensity, and genetic signature; a genomics-based rare-disease patient prevalence platform to inform licensing/acquisition opportunities; and AI-based phenotype- and genome-driven rare-disease diagnosis decision-support systems. In parallel to his DGB responsibilities at Alexion, Dr. Reynders also led the R&D strategy, portfolio and project management department, leading efforts across R&D capability strategy, pipeline project management, portfolio optimization, governance, and R&D operating models. Prior to joining Alexion, Dr. Reynders served as CIO of Moderna Therapeutics, where he created a fully cloud-based biotech across all enterprise functions and developed informatics solutions to enable the design of messenger RNA therapeutics. Previously, John served as Vice President of R&D Information at AstraZeneca R&D leading teams in the US, UK, Sweden, Russia, Japan, and China to enable discovery, translational, clinical, pharmaceutical development, and regulatory functions. Before this, John served in leadership roles at Johnson & Johnson including VP Integrative Neuroscience and Biomarkers, Head of Informatics, and VP R&D Information Technology. Previously, John served as Information Officer with Lilly Research Laboratories, VP of Informatics at Celera Genomics, and held roles as Director and Program Manager at the Los Alamos National Laboratory. Dr. Reynders received a Bachelors, Summa Cum Laude, in Mathematics from Rensselaer Polytechnic Institute, a PhD in Applied and Computational Mathematics from Princeton University, and a Masters of Business Administration from the Northwestern University Kellogg School of Management.


3:55 PM - 4:25 PM

An AI Powered Project: Human Genetics & Drug Discovery

This session will discuss various projects and their potential impact on the industry when the big data derived from the human genome is married with breakthroughs from artificial intelligence.


  • Dr. Gunaretnam (Guna) Rajagopal

    Dr. Gunaretnam (Guna) Rajagopal VP Global Head – Computational Sciences, Discovery Sciences Janssen Research & Development, A Johnson & Johnson Company


  • John Reynders

    John Reynders Vice President, Data Science, Genomics, and Bioinformatics Alexion Pharmaceuticals, Inc.

    • Answering the question “how many rare diseases are there?” and navigating the rare-disease landscape with data sciences
    • If Amazon can recommend a book we might like, can we use AI to help a doctor ask the next right question to enable a rare-disease diagnosis?
    • How to set a world record in rare-disease diagnosis – hint: genomics + AI
  • Panna Sharma

    Panna Sharma CEO Lantern Pharma

    • How Lantern Pharma is revolutionizing the drug development process by implementing its RADR platform, which leverages AI, ML and genomics, to increase clinical trial success rates as well as reduce timelines and costs.
    • Use Cases for drugs LP100, LP184 and LP300

Download Latest Agenda